Aurinia Pharmaceuticals stock (CA05156H1070): shares steady as Nasdaq-listed biotech advances myasthenia gravis trial plans

Aurinia Pharmaceuticals shares traded around the mid-teens on Nasdaq on 06/02/2026, with fresh attention on the Canadian biotech after its 05/19/2026 announcement that it will enroll patients with generalized myasthenia gravis in a new clinical study.

Aurinia Pharmaceuticals, whose shares trade on Nasdaq under the ticker AUPH, saw its stock change hands in the mid-teens in USD on 06/01/2026, keeping the Canada-based biotech in focus after a recent update on its development pipeline for autoimmune disease.

According to Nasdaq price data cited by several market platforms, Aurinia Pharmaceuticals closed at roughly USD 15 per share on 06/01/2026 on the Nasdaq Global Market, underscoring the company’s continued presence in the United States as its main trading venue and reference market for equity investors.

The stock traded at about USD 15.31 on 06/01/2026, based on data compiled by MarketBeat from Nasdaq, reflecting marginal day-on-day movement of roughly 0.1 percent in regular trading hours for Aurinia Pharmaceuticals shares on the US market.

This US quote complements Aurinia Pharmaceuticals’ home-country profile as a Canadian-headquartered biopharmaceutical group whose equity story is nonetheless strongly anchored in the United States via its Nasdaq listing and visibility among US healthcare investors.

The latest fundamental trigger for the stock came on 05/19/2026, when Aurinia Pharmaceuticals announced plans to enroll patients with generalized myasthenia gravis (gMG) in a new clinical study, adding another autoimmune indication to its development pipeline beyond existing nephrology-focused programs.

In that 05/19/2026 update, highlighted by DelveInsight’s coverage of the myasthenia gravis pipeline, the company positioned its planned gMG trial within a broader competitive landscape in which more than 20 pharmaceutical companies are working on similar indications in neuromuscular autoimmune disease.

This prospective gMG study underscores Aurinia Pharmaceuticals’ effort to diversify potential revenue sources over time by testing its expertise in immune modulation in a disease area that has drawn increasing R&D investment and licensing activity across global pharma.

At the same time, trading data show that investor positioning in Aurinia Pharmaceuticals remains active: as of 05/15/2026, MarketBeat reported short interest of about 9.02 million AUPH shares, equivalent to roughly 7.99 percent of the public float, indicating a notable level of bearish positioning in the market.

MarketBeat added that this short interest figure for Aurinia Pharmaceuticals as of 05/15/2026 represented an increase of about 1.6 percent from the prior report of 8.89 million shares sold short, with a short interest ratio of 6.8 days based on average daily trading volume of approximately 1.24 million shares.

The stock’s combination of pipeline developments and an elevated short-interest profile means that any further clinical or regulatory news around Aurinia Pharmaceuticals’ programs, including the planned gMG study, could translate into visible share-price reactions on Nasdaq.

As of: 03/06/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Aurinia Pharmaceuticals
• Sector/industry: Biopharmaceuticals, autoimmune and renal disease therapies
• Headquarters/country: Victoria, Canada
• Core markets: United States and Canada for commercialization; global reach for clinical development
• Key revenue drivers: Specialty therapies targeting autoimmune conditions such as lupus nephritis, with additional value potential from pipeline indications including generalized myasthenia gravis
• Home exchange/listing venue: Nasdaq Global Market (AUPH)
• Trading currency: USD

Aurinia Pharmaceuticals: core business model

Aurinia Pharmaceuticals focuses on developing and marketing specialty biopharmaceutical treatments for autoimmune-driven kidney and systemic diseases, with sales primarily tied to its lead therapy and future contribution expected from late-stage pipeline assets in related indications.

Aurinia Pharmaceuticals in peer comparison

Placed within the broader North American biotech landscape, Aurinia Pharmaceuticals is often compared by investors to other mid-cap US-listed specialty biopharma names targeting autoimmune and neurology indications, including Catalyst Pharmaceuticals and similar Nasdaq-traded peers.

Data from Simply Wall St on 06/02/2026 show that Catalyst Pharmaceuticals, which trades on Nasdaq under the ticker CPRX, is also active in neuromuscular and rare disease therapies, with a valuation framework that highlights how the market assesses cash-generative specialty pharma stories versus those such as Aurinia Pharmaceuticals that remain more dependent on pipeline milestones.

Conclusion

With Aurinia Pharmaceuticals’ share price holding in the mid-teens on Nasdaq on 06/01/2026 and short interest approaching 8 percent of the float, the market is closely monitoring both trading dynamics and clinical execution.

The planned generalized myasthenia gravis study, disclosed on 05/19/2026, expands Aurinia Pharmaceuticals’ reach beyond its established kidney-disease focus, while peer comparisons with other US-listed specialty biopharma groups underline how investors distinguish between cash-flow profiles and pipeline-heavy stories.

How effectively Aurinia Pharmaceuticals advances this and other programs through clinical milestones against a crowded autoimmune-therapy peer set is likely to remain a central question for investors following the stock on Nasdaq Global Market.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.